FLT3 programme licensing opportunity
Sentinel Oncology is pleased to announce that its FLT3 kinase programme is available for partnering.
Mutations in the FLT3 gene are amongst the most frequent genetic defects found in acute myeloid leukemia (AML). Sentinel Oncology has developed a novel lead series of small molecule drugs which act as potent inhibitors of FLT3 and represent an excellent opportunity to develop pre-clinical candidate drugs... read more
For more information about the Sentinel Oncology p70S6 kinase programme, visit our website at www.sentineloncology.com or contact us to arrange a collaborative discussion.
March 30, 2010
Sentinel Oncology will be participating in the following events
23rd - 26th June 2014
BIO - San Diego
3rd - 5th November 2014
BIO Europe - Frankfurt